Cargando…

Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia

BACKGROUND AND AIM: The eradication of H. pylori infection using PPI associated with different combinations of two or three antibiotics entails high risks of side effects and non- adherence. Therefore probiotics have been proposed for H. pylori eradication. We tested the efficacy of Lactobacillus re...

Descripción completa

Detalles Bibliográficos
Autores principales: Muresan, Iulia Antonia Pop, Pop, Lucian Liviu, Dumitrascu, Dan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853040/
https://www.ncbi.nlm.nih.gov/pubmed/31750434
http://dx.doi.org/10.15386/mpr-1375
_version_ 1783469973280129024
author Muresan, Iulia Antonia Pop
Pop, Lucian Liviu
Dumitrascu, Dan L.
author_facet Muresan, Iulia Antonia Pop
Pop, Lucian Liviu
Dumitrascu, Dan L.
author_sort Muresan, Iulia Antonia Pop
collection PubMed
description BACKGROUND AND AIM: The eradication of H. pylori infection using PPI associated with different combinations of two or three antibiotics entails high risks of side effects and non- adherence. Therefore probiotics have been proposed for H. pylori eradication. We tested the efficacy of Lactobacillus reuteri plus Pantoprazole compared to a triple regimen based on Pantoprazole plus Amoxicillin plus Clarithromycin in patients with H. pylori infection and functional dyspepsia. METHODS: In a prospective design, 46 patients (M: 13, F: 33, mean age 48.80 ± 13.82 years) fulfilled the following inclusion criteria: age at least 18, documented informed consent, positive H. pylori finding by histology, no morphological changes of the gastric mucosa at upper gastrointestinal endoscopy and complaints of functional dyspepsia according to the Rome III criteria. Exclusion criteria were: presence of any other chronic organic diseases that required drug treatment, use of antibiotics, PPIs or H2 antagonists in the previous 3 months; pregnancy or lactation. Patients were randomly divided into two equal groups (23 patients each group). One group received the standard therapy in our area: Pantoprazole 40 mg bid for 30 days associated with Amoxicillin 2×1000 mg/day and Clarithromycin 500 mg bid for 14 days. The other group received Pantoprazole 40 mg/day plus L. reuteri DSMZ 17648 twice a day for 8 weeks. Post-treatment eradication was tested by H. pylori antigen stool assay at 30 days after therapy. RESULTS: The group on L. reuteri plus Pantoprazole presented 65.22% eradication rate compared to 73.91% cure rate in the group that received the Pantoprazole and Amoxicillin and Clarithromycin therapy, with no statistically significant difference in eradication rate between the two groups (p=0.75). The total adherence was good and eradication of H. pylori was associated with improvement of dyspeptic symptoms for both eradication regimens. CONCLUSION: L. reuteri is a good alternative for patients with chronic dyspepsia for the eradication of H. pylori infection. Its efficacy is similar to the triple therapy.
format Online
Article
Text
id pubmed-6853040
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Iuliu Hatieganu University of Medicine and Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-68530402019-11-20 Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia Muresan, Iulia Antonia Pop Pop, Lucian Liviu Dumitrascu, Dan L. Med Pharm Rep Original Research BACKGROUND AND AIM: The eradication of H. pylori infection using PPI associated with different combinations of two or three antibiotics entails high risks of side effects and non- adherence. Therefore probiotics have been proposed for H. pylori eradication. We tested the efficacy of Lactobacillus reuteri plus Pantoprazole compared to a triple regimen based on Pantoprazole plus Amoxicillin plus Clarithromycin in patients with H. pylori infection and functional dyspepsia. METHODS: In a prospective design, 46 patients (M: 13, F: 33, mean age 48.80 ± 13.82 years) fulfilled the following inclusion criteria: age at least 18, documented informed consent, positive H. pylori finding by histology, no morphological changes of the gastric mucosa at upper gastrointestinal endoscopy and complaints of functional dyspepsia according to the Rome III criteria. Exclusion criteria were: presence of any other chronic organic diseases that required drug treatment, use of antibiotics, PPIs or H2 antagonists in the previous 3 months; pregnancy or lactation. Patients were randomly divided into two equal groups (23 patients each group). One group received the standard therapy in our area: Pantoprazole 40 mg bid for 30 days associated with Amoxicillin 2×1000 mg/day and Clarithromycin 500 mg bid for 14 days. The other group received Pantoprazole 40 mg/day plus L. reuteri DSMZ 17648 twice a day for 8 weeks. Post-treatment eradication was tested by H. pylori antigen stool assay at 30 days after therapy. RESULTS: The group on L. reuteri plus Pantoprazole presented 65.22% eradication rate compared to 73.91% cure rate in the group that received the Pantoprazole and Amoxicillin and Clarithromycin therapy, with no statistically significant difference in eradication rate between the two groups (p=0.75). The total adherence was good and eradication of H. pylori was associated with improvement of dyspeptic symptoms for both eradication regimens. CONCLUSION: L. reuteri is a good alternative for patients with chronic dyspepsia for the eradication of H. pylori infection. Its efficacy is similar to the triple therapy. Iuliu Hatieganu University of Medicine and Pharmacy 2019-10 2019-10-25 /pmc/articles/PMC6853040/ /pubmed/31750434 http://dx.doi.org/10.15386/mpr-1375 Text en This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Research
Muresan, Iulia Antonia Pop
Pop, Lucian Liviu
Dumitrascu, Dan L.
Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title_full Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title_fullStr Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title_full_unstemmed Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title_short Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
title_sort lactobacillus reuteri versus triple therapy for the eradication of helicobacter pylori in functional dyspepsia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853040/
https://www.ncbi.nlm.nih.gov/pubmed/31750434
http://dx.doi.org/10.15386/mpr-1375
work_keys_str_mv AT muresaniuliaantoniapop lactobacillusreuteriversustripletherapyfortheeradicationofhelicobacterpyloriinfunctionaldyspepsia
AT poplucianliviu lactobacillusreuteriversustripletherapyfortheeradicationofhelicobacterpyloriinfunctionaldyspepsia
AT dumitrascudanl lactobacillusreuteriversustripletherapyfortheeradicationofhelicobacterpyloriinfunctionaldyspepsia